Optimal condition of heparin-conjugated fibrin with bone morphogenetic protein-2 for spinal fusion in a rabbit model

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1441-1448

  Hong, Jae Young ^a   Kang, Sun Woong ^b   Kim, Jung Wook ^a   Suh, Seung Woo ^c   Ko, You Jin ^a   Park, Jung Ho ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Autograft; BMP 2; Heparin conjugated fibrin; Spinal fusion

Indexed keywords

FIBRIN DERIVATIVE; HEPARIN CONJUGATED FIBRIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN 2; DRUG CARRIER; DRUG IMPLANT; FIBRIN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE GRAFT; BONE REGENERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; RABBIT MODEL; SPINE FUSION; SPINE RADIOGRAPHY; ANIMAL; ANIMAL MODEL; BONE DEVELOPMENT; CHEMISTRY; DRUG EFFECTS; DRUG IMPLANT; PATHOLOGY; PROCEDURES; RABBIT; RADIOGRAPHY; SPINE; SURGERY; TREATMENT OUTCOME;

ORYCTOLAGUS CUNICULUS;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG IMPLANTS; FIBRIN; HEPARIN; MODELS, ANIMAL; OSTEOGENESIS; RABBITS; SPINAL FUSION; SPINE; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 84908509079     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.04.005     Document Type: Article

References (21)

1. Deyo R.A., Ching A., Matsen L., Martin B.I., Kreuter W., Jarvik J.G., et al. Use of bone morphogenetic proteins in spinal fusion surgery for older adults with lumbar stenosis: trends, complications, repeat surgery, and charges. Spine 2012, 37:222-230.
2. Sheehan J.P., Sheehan J.M., Seeherman H., Quigg M., Helm G.A. The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model. JNeurosurg 2003, 98:125-130.
3. Harwood P.J., Giannoudis P.V. Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects. Expert Opin Drug Saf 2005, 4:75-89.
4. Koo K.H., Lee J.M., Ahn J.M., Kim B.S., La W.G., Kim C.S., Im G.I. Controlled delivery of low-dose bone morphogenetic protein-2 using heparin-conjugated fibrin in the posterolateral lumbar fusion of rabbits. Artif Organs 2013, 37:487-494.
5. Koo K.H., Yeo do H., Ahn J.M., Kim B.S., Kim C.S., Im G.I. Lumbar posterolateral fusion using heparin-conjugated fibrin for sustained delivery of bone morphogenic protein-2 in a rabbit model. Artif Organs 2012, 36:629-634.
6. La W.G., Kwon S.H., Lee T.J., Yang H.S., Park J., Kim B.S. The effect of the delivery carrier on the quality of bone formed via bone morphogenetic protein-2. Artif Organs 2012, 36:642-647.
7. Yang H.S., La W.G., Bhang S.H., Jeon J.Y., Lee J.H., Kim B.S. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010, 16:1225-1233.
8. Yang H.S., La W.G., Cho Y.M., Shin W., Yeo G.D., Kim B.S. Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration. Exp Mol Med 2012, 44:350-355.
9. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
10. Boden S.D., Schimandle J.H., Hutton W.C. An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine 1995, 20:412-420.
11. Grauer J.N., Patel T.C., Erulkar J.S., Troiano N.W., Panjabi M.M., Friedlaeder G.E. 2000 Young Investigator Research Award winner. Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion. Spine 2001, 26:127-133.
12. Lu J., Bhargav D., Wei A.Q., Diwan A. Posterolateral intertransverse spinal fusion possible in osteoporotic rats with BMP-7 in a higher dose delivered on a composite carrier. Spine 2008, 33:242-249.
13. Moazzaz P., Gupta M.C., Gilotra M.M., Gilotra M.N., Maitra S., Theerajunyaporn T., et al. Estrogen-dependent actions of bone morphogenetic protein-7 on spine fusion in rats. Spine 2005, 30:1706-1711.
14. Lad S.P., Nathan J.K., Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine 2011, 36:E274-E281.
15. Docherty S.A., Engstrand T. Bone morphogenetic proteins in cranial reconstructions: clinical evaluation of heparin-chitosan as a carrier for BMP-2. Plast Reconstr Surg 2009, 123:192e-193e.
16. Jeon O., Powell C., Solorio L.D., Krebs M.D., Alsberg E. Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels. JControl Release 2011, 154:258-266.
17. Jeon O., Song S.J., Yang H.S., Bhang S.H., Kang S.W., Sung M.A., et al. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008, 369:774-780.
18. Kim S.E., Jeon O., Lee J.B., Bae M.S., Chun H.J., Moon S.H., Kwon I.K. Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells. JBiomed Sci 2008, 15:771-777.
19. Lee J.W., Lee S., Lee S.H., Yang H.S., Im G.I., Kim C.S., et al. Improved spinal fusion efficacy by long-term delivery of bone morphogenetic protein-2 in a rabbit model. Acta Orthop 2011, 82:756-760.
20. Zhao B., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. JBiol Chem 2006, 281:23246-23253.
21. Kato M., Toyoda H., Namikawa T., Hoshino M., Terai H., Miyamoto S., Takaoka K. Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). Biomaterials 2006, 27:2035-2041.